Back to the main directory
EarningsReview / Equity
- Nursed back to health by BNP Paribas Exane
- Blocking And Tackling by BNP Paribas Exane
- No Easy Fixes: Maintain Neutral Rating Post 1Q25 Pre-Quiet Period Call by BNP Paribas Exane
- Mining Momentum Monitor by BNP Paribas Exane
- FY24 results: EBITDA in line, c. +8% upside to FY25e FCF consensus on “new base”, current trading looking fine to end February by BNP Paribas Exane
- FY results first take: good finish, slow start by BNP Paribas Exane
- 4Q 24: Limited new guidance, expect a neutral share price response by BNP Paribas Exane
- Luberef (LUBEREF AB) by HSBC
- FY24: core op profit in-line by BNP Paribas Exane
- Esprinet - Des résultats annuels positifs by MidCap Partners
- Lumibird - Optimisme prudent pour 2025 by MidCap Partners
- Europe’s moment (presentation) by BNP Paribas Exane
- 4Q24 - 24 targets met, strong FCF, 25 guidance realistic, at least by BNP Paribas Exane
- Groupe Pizzorno Env. - In ligne, acceleration in 2025 by MidCap Partners
- Esprinet - Positive Annual Results by MidCap Partners
- Non material data changes by BNP Paribas Exane
- MINING MONITOR, BHP, GOLD/NEM, EU SAFEGUARDS, CHINA AUTO by BNP Paribas Exane
- FY results: off the call by BNP Paribas Exane
- Europe’s moment: Saint Gobain by BNP Paribas Exane
- The next era: Debenhams Group by BNP Paribas Exane
- China Cybersecurity by HSBC
- Q4 Earnings Call Feedback by BNP Paribas Exane
- Nien Made (8464 TT) by HSBC
- Itaú BBA on Arcos Dorados: Expected End to 2024 Ex One Offs by Itau
- Key Takeaways from Pou Sheng/Yue Yuen by BNP Paribas Exane